Mithat Gonen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Mithat Gonen has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
- Vinod P. Balachandran
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
50 shared publications - Alice C. Wei
Hepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, USA
49 shared publications William R. Jarnagin
Hepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, USA
44 shared publications- Carlie Sigel
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, USA
41 shared publications - Charles M. Rudin
Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
40 shared publications T. Peter Kingham
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY
38 shared publications
Latest Publications
- 10 November 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (32) , 3105-3115
Financial Payments From Drug Manufacturers to Oncologists and Use of Guideline-Preferred Cancer Treatments
PURPOSE: Payments from the drug industry influence physicians' prescribing decisions. Whether industry payments affect the likelihood that patients receive the guideline-preferred treatment for their cancer is unknown. METHODS: We used fee-for-service Medicare claims to identify patients with an incident cancer diagnosis from 2014 to 2020. We used the National Comprehensive Cancer Network (NCCN) guidelines to identify cancers with variation in clinical benefit among recommended treatment options and to identify the preferred treatment as of each patient's diagnosis date. The primary exposure was drug industry payments received by the patient's medical oncologist during the year before diagnosis, categorized as no payment, payment for preferred treatment only, payment for nonpreferred treatment only, or payment for both. The primary outcome was receipt of a preferred treatment. RESULTS: There were 14 cancer scenarios comprising 15,607 patients; 60.2% were managed by oncologists who received no payment, 21.9% by oncologists who received payment for guideline-preferred treatment, 30.6% by oncologists who received payment for nonpreferred treatment, and 12.7% by oncologists who received both payment types. Among patients whose oncologist received no payments, 41.6% received payments for preferred treatment versus 51.5% of those whose oncologist received payments for guideline-preferred treatment only, 34.7% of those whose oncologist received payments for nonpreferred treatment only, and 42.9% of those whose oncologist received payments for both payment types. After adjustment, payment for guideline-preferred treatment was associated with a greater likelihood of receiving preferred treatment (risk ratio [RR] = 1.06 [95% CI, 1.01 to 1.13]) and payment for nonpreferred treatment was associated with a lower likelihood (RR, 0.93 [95% CI, 0.89 to 0.98]). Association magnitude increased as payment dollar value increased. CONCLUSION: Industry payments were associated with increased use of the promoted cancer treatment, regardless of whether that treatment was guideline-preferred or nonpreferred for a given patient.
- 10 November 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (32) , 3105-3115
Financial Payments From Drug Manufacturers to Oncologists and Use of Guideline-Preferred Cancer Treatments
PURPOSE: Payments from the drug industry influence physicians' prescribing decisions. Whether industry payments affect the likelihood that patients receive the guideline-preferred treatment for their cancer is unknown. METHODS: We used fee-for-service Medicare claims to identify patients with an incident cancer diagnosis from 2014 to 2020. We used the National Comprehensive Cancer Network (NCCN) guidelines to identify cancers with variation in clinical benefit among recommended treatment options and to identify the preferred treatment as of each patient's diagnosis date. The primary exposure was drug industry payments received by the patient's medical oncologist during the year before diagnosis, categorized as no payment, payment for preferred treatment only, payment for nonpreferred treatment only, or payment for both. The primary outcome was receipt of a preferred treatment. RESULTS: There were 14 cancer scenarios comprising 15,607 patients; 60.2% were managed by oncologists who received no payment, 21.9% by oncologists who received payment for guideline-preferred treatment, 30.6% by oncologists who received payment for nonpreferred treatment, and 12.7% by oncologists who received both payment types. Among patients whose oncologist received no payments, 41.6% received payments for preferred treatment versus 51.5% of those whose oncologist received payments for guideline-preferred treatment only, 34.7% of those whose oncologist received payments for nonpreferred treatment only, and 42.9% of those whose oncologist received payments for both payment types. After adjustment, payment for guideline-preferred treatment was associated with a greater likelihood of receiving preferred treatment (risk ratio [RR] = 1.06 [95% CI, 1.01 to 1.13]) and payment for nonpreferred treatment was associated with a lower likelihood (RR, 0.93 [95% CI, 0.89 to 0.98]). Association magnitude increased as payment dollar value increased. CONCLUSION: Industry payments were associated with increased use of the promoted cancer treatment, regardless of whether that treatment was guideline-preferred or nonpreferred for a given patient.
- 29 October 2026
- Published by Wiley in Journal of Surgical Oncology
Changes in Multidisciplinary Management of Locally Advanced Rectal Cancer at a Comprehensive Cancer Center From 2015 to 2023
Background: Multidisciplinary management of locally advanced rectal cancer (LARC) has evolved rapidly over the past decade, guided by data from multiple prospective clinical trials. Methods: Changes in treatment of cT3‐4 or N+ rectal cancer at a comprehensive cancer center between 2015 and 2023 were analyzed retrospectively. Results: Of 1121 patients who received neoadjuvant therapy, 793 (71%) underwent active surveillance and 328 (29%) underwent surgery within 3 months. Treatments whose use increased from 2015 to 2023 included TNT with consolidation chemotherapy (from 10% to 81%), neoadjuvant chemotherapy alone (from 13% to 21%), immunotherapy or targeted therapy (from 0% to 10%), and oral capecitabine versus intravenous fluorouracil in combination with oxaliplatin (from 4% to 56%). Among patients who received TNT, nonoperative management with sustained clinical complete response rose from 38% to 50%. With more patients undergoing nonoperative management, the rate of pathologic complete response decreased from 22% to 8.3%. Robotic assistance was used in 88% of surgeries. Conclusions: The adoption of new diagnostic and treatment paradigms allows for longer intervals until surgery, more frequent use of active surveillance, and higher rates of organ preservation without compromising safety or oncologic outcomes.
- 29 October 2026
- Published by Wiley in Journal of Surgical Oncology
Changes in Multidisciplinary Management of Locally Advanced Rectal Cancer at a Comprehensive Cancer Center From 2015 to 2023
Background: Multidisciplinary management of locally advanced rectal cancer (LARC) has evolved rapidly over the past decade, guided by data from multiple prospective clinical trials. Methods: Changes in treatment of cT3‐4 or N+ rectal cancer at a comprehensive cancer center between 2015 and 2023 were analyzed retrospectively. Results: Of 1121 patients who received neoadjuvant therapy, 793 (71%) underwent active surveillance and 328 (29%) underwent surgery within 3 months. Treatments whose use increased from 2015 to 2023 included TNT with consolidation chemotherapy (from 10% to 81%), neoadjuvant chemotherapy alone (from 13% to 21%), immunotherapy or targeted therapy (from 0% to 10%), and oral capecitabine versus intravenous fluorouracil in combination with oxaliplatin (from 4% to 56%). Among patients who received TNT, nonoperative management with sustained clinical complete response rose from 38% to 50%. With more patients undergoing nonoperative management, the rate of pathologic complete response decreased from 22% to 8.3%. Robotic assistance was used in 88% of surgeries. Conclusions: The adoption of new diagnostic and treatment paradigms allows for longer intervals until surgery, more frequent use of active surveillance, and higher rates of organ preservation without compromising safety or oncologic outcomes.
- 19 October 2026
- Published by Wolters Kluwer Health in Annals of Surgery
Technical Complications and Salvage of Hepatic Artery Infusion Pumps
Objective: Describe the technical complications of hepatic artery infusion pump (HAIP) placement and characterize salvage rates. Summary Background Data: HAIP chemotherapy is an effective tool used in the treatment of hepatic malignancies and has become increasingly adopted at select centers. Much of the safety data is reported from small, newer programs or older, large series. Methods: Retrospective analysis of all patients who underwent HAIP placement at our institution between 2000 and 2022 was conducted. Pump salvage was defined as the ability to receive HAIP chemotherapy after a pump-associated complication. Pump failure was defined as an HAIP-related complication permanently stopping ongoing HAIP chemotherapy. Results: Over the study period, 2935 patients had an HAIP placed for colorectal liver metastases (n=2582, 88%), intrahepatic cholangiocarcinoma (n=294, 10%) or another malignancy (n=59, 2%). Of all patients, 759 (26%) had an HAIP-related complication, with 404/759 (53%) having their pump salvaged. The most common complications were abnormal perfusion (n=360 [12%], 285/360 [79%] salvaged), arterial pseudoaneurysm and/or hemorrhage (n=117 [4%], 7/117 [6%] salvaged), and pump-pocket infection (n=115 [4%], 60/115 [52%] salvaged). The complications with the highest salvage rates were pump-pocket seroma (n=15/16, 94%), pump-flipping (n=41/44, 93%), and pump-pocket hematoma (n=45/49, 92%). Unsalvaged complications were catheter dislodgement from vessel (n=0/47, 0%), catheter erosion into bowel (n=0/25, 0%), and arterial thrombosis (n=0/19, 0%). The cumulative incidence of pump failure at 1 year in patients receiving adjuvant therapy was 6.6%, and 4.5% among those receiving palliative therapy. Conclusions: HAIP-related complications occur in about one quarter of patients, predominantly perfusion and pump-pocket complications. These are salvageable in the majority of cases with multidisciplinary interventions.
- 19 October 2026
- Published by Wolters Kluwer Health in Annals of Surgery
Technical Complications and Salvage of Hepatic Artery Infusion Pumps
Objective: Describe the technical complications of hepatic artery infusion pump (HAIP) placement and characterize salvage rates. Summary Background Data: HAIP chemotherapy is an effective tool used in the treatment of hepatic malignancies and has become increasingly adopted at select centers. Much of the safety data is reported from small, newer programs or older, large series. Methods: Retrospective analysis of all patients who underwent HAIP placement at our institution between 2000 and 2022 was conducted. Pump salvage was defined as the ability to receive HAIP chemotherapy after a pump-associated complication. Pump failure was defined as an HAIP-related complication permanently stopping ongoing HAIP chemotherapy. Results: Over the study period, 2935 patients had an HAIP placed for colorectal liver metastases (n=2582, 88%), intrahepatic cholangiocarcinoma (n=294, 10%) or another malignancy (n=59, 2%). Of all patients, 759 (26%) had an HAIP-related complication, with 404/759 (53%) having their pump salvaged. The most common complications were abnormal perfusion (n=360 [12%], 285/360 [79%] salvaged), arterial pseudoaneurysm and/or hemorrhage (n=117 [4%], 7/117 [6%] salvaged), and pump-pocket infection (n=115 [4%], 60/115 [52%] salvaged). The complications with the highest salvage rates were pump-pocket seroma (n=15/16, 94%), pump-flipping (n=41/44, 93%), and pump-pocket hematoma (n=45/49, 92%). Unsalvaged complications were catheter dislodgement from vessel (n=0/47, 0%), catheter erosion into bowel (n=0/25, 0%), and arterial thrombosis (n=0/19, 0%). The cumulative incidence of pump failure at 1 year in patients receiving adjuvant therapy was 6.6%, and 4.5% among those receiving palliative therapy. Conclusions: HAIP-related complications occur in about one quarter of patients, predominantly perfusion and pump-pocket complications. These are salvageable in the majority of cases with multidisciplinary interventions.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Molecular and Clinical Determinants of Targeted Therapy Treatment in Biliary Tract Cancer
Supplemental Figure 1: Consort diagram depicting patient/sample exclusions. Untreated groups are at an alteration level, where patients harboring the specific alteration are included in the groups; patients can be in more than one untreated group. Treatment groups are determined by the matched therapy that the patient received.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Molecular and Clinical Determinants of Targeted Therapy Treatment in Biliary Tract Cancer
Supplemental Figure 1: Consort diagram depicting patient/sample exclusions. Untreated groups are at an alteration level, where patients harboring the specific alteration are included in the groups; patients can be in more than one untreated group. Treatment groups are determined by the matched therapy that the patient received.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Molecular and Clinical Determinants of Targeted Therapy Treatment in Biliary Tract Cancer
Supplemental Figure 2: A. Comparison of gene-level alterations showing significant differences across BTC subtypes. B. Comparison of oncogenic signaling pathway alterations across BTC subtypes. C. Comparison of gene-level alteration between different age groups divided into decades. D. Percentage of samples with clonal, subclonal, and indeterminate mutations broken down by subtype. Proportion of clonal, subclonal, and indeterminate mutations broken down by subtypes. E. Oncoprint comparing the tumors with subclonal ERBB2 mutations to those with clonal mutations. F. Comparison of actionability in 2017 and 2023 across subtypes. G. Percentage of patients getting targeted therapy over the years, with drug approvals plotted below. Fifteen patients who received HAI treatment only, as well as 1 patient treated outside of MSK, were excluded from the plot.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Molecular and Clinical Determinants of Targeted Therapy Treatment in Biliary Tract Cancer
Supplemental Figure 2: A. Comparison of gene-level alterations showing significant differences across BTC subtypes. B. Comparison of oncogenic signaling pathway alterations across BTC subtypes. C. Comparison of gene-level alteration between different age groups divided into decades. D. Percentage of samples with clonal, subclonal, and indeterminate mutations broken down by subtype. Proportion of clonal, subclonal, and indeterminate mutations broken down by subtypes. E. Oncoprint comparing the tumors with subclonal ERBB2 mutations to those with clonal mutations. F. Comparison of actionability in 2017 and 2023 across subtypes. G. Percentage of patients getting targeted therapy over the years, with drug approvals plotted below. Fifteen patients who received HAI treatment only, as well as 1 patient treated outside of MSK, were excluded from the plot.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Molecular and Clinical Determinants of Targeted Therapy Treatment in Biliary Tract Cancer
Supplemental Figure 3: A. Swimmers plot showing progressing free survival from the start of second-line therapy comparing patients who received 5-fu based treatment versus targeted therapy. B. Survival curve depicting overall survival from the start of second-line therapy comparing treated and untreated patients, excluding those treated with immunotherapy. To address the potential lead time bias, the treated group was restricted to patients who received targeted treatment in the second line, and the untreated group was restricted to patients who received 2 or more lines of systemic therapy. C. Survival curve depicting overall survival from the start of second-line therapy comparing treated and untreated patients with an OncoKB level 1 or level 2 alteration. To address the potential lead time bias, the treated group was restricted to patients who received targeted treatment in the second line, and the untreated group was restricted to patients who received 2 or more lines of systemic therapy. D. Swimmers plot showing the progression-free survival in BRAFi-treated patients. Kaplan–Meier overall survival curves comparing patients harboring BRAF class I mutation with a targeted therapy to those who did not. E. Swimmers plots of overall survival comparing treated and untreated targeted therapy cohorts (IDH1/2 mutated, FGFR2i-treated, and ERBB2i-treated patients). F. Kaplan–Meier overall curves comparing overall survival from the start of second-line therapy between treated and untreated samples in the entire immunotherapy cohort, then stratified into MSI patients and TMB-high patient subgroups. To address the potential lead time bias, the treated group was restricted to patients who received targeted treatment in the second line, and the untreated group was restricted to patients who received 2 or more lines of systemic therapy. G. Swimmer’s plot depicting the progression-free survival in patients treated with immunotherapy, with an oncoprint depicting genes commonly altered in MSI tumors and a proportionality plot for the types of mutations within each tumor and sample-level TMB and MSI annotations.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Molecular and Clinical Determinants of Targeted Therapy Treatment in Biliary Tract Cancer
Supplemental Figure 3: A. Swimmers plot showing progressing free survival from the start of second-line therapy comparing patients who received 5-fu based treatment versus targeted therapy. B. Survival curve depicting overall survival from the start of second-line therapy comparing treated and untreated patients, excluding those treated with immunotherapy. To address the potential lead time bias, the treated group was restricted to patients who received targeted treatment in the second line, and the untreated group was restricted to patients who received 2 or more lines of systemic therapy. C. Survival curve depicting overall survival from the start of second-line therapy comparing treated and untreated patients with an OncoKB level 1 or level 2 alteration. To address the potential lead time bias, the treated group was restricted to patients who received targeted treatment in the second line, and the untreated group was restricted to patients who received 2 or more lines of systemic therapy. D. Swimmers plot showing the progression-free survival in BRAFi-treated patients. Kaplan–Meier overall survival curves comparing patients harboring BRAF class I mutation with a targeted therapy to those who did not. E. Swimmers plots of overall survival comparing treated and untreated targeted therapy cohorts (IDH1/2 mutated, FGFR2i-treated, and ERBB2i-treated patients). F. Kaplan–Meier overall curves comparing overall survival from the start of second-line therapy between treated and untreated samples in the entire immunotherapy cohort, then stratified into MSI patients and TMB-high patient subgroups. To address the potential lead time bias, the treated group was restricted to patients who received targeted treatment in the second line, and the untreated group was restricted to patients who received 2 or more lines of systemic therapy. G. Swimmer’s plot depicting the progression-free survival in patients treated with immunotherapy, with an oncoprint depicting genes commonly altered in MSI tumors and a proportionality plot for the types of mutations within each tumor and sample-level TMB and MSI annotations.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Molecular and Clinical Determinants of Targeted Therapy Treatment in Biliary Tract Cancer
Supplemental Figure 4: A. Bar plot showing shared and unshared mutations between pre- and post-treatment samples. B. Oncoprint comparing pre- and post-treatment samples in ERBB2, FGFR2, and BRAF treatment cohorts. C. Lollipop plots for specific mutations in KRAS and MAP2K1 detected in the sequential samples from the BRAF targeted therapy-treated patient.
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Molecular and Clinical Determinants of Targeted Therapy Treatment in Biliary Tract Cancer
Supplemental Figure 4: A. Bar plot showing shared and unshared mutations between pre- and post-treatment samples. B. Oncoprint comparing pre- and post-treatment samples in ERBB2, FGFR2, and BRAF treatment cohorts. C. Lollipop plots for specific mutations in KRAS and MAP2K1 detected in the sequential samples from the BRAF targeted therapy-treated patient.
- Open Access
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S10 from Molecular and Clinical Determinants of Targeted Therapy Treatment in Biliary Tract Cancer
Table S1. Cohort demographics Table S2: Clinically eligible for matched-targeted therapy cohort demographics of molecularly defined Subgroups Table S3: Genes included on MSK-IMPACT Panels Table S4: Comparison of gene-level alteration frequency by BTC Subtypes Table S5: Comparison of pathway-level alteration frequency by BTC Subtypes Table S6: Actionable alterations in patients without targeted therapy due to unavailability Table S7: Comparison of clinical characteristics between treatment groups Table S8: Comparison of gene-level alterations between treatment groups Table S9: Summary of OS univariate analysis (Full cohort) Table S10: Overall Survival analysis of Molecularly Defined Subgroups
- 15 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S10 from Molecular and Clinical Determinants of Targeted Therapy Treatment in Biliary Tract Cancer
Table S1. Cohort demographics Table S2: Clinically eligible for matched-targeted therapy cohort demographics of molecularly defined Subgroups Table S3: Genes included on MSK-IMPACT Panels Table S4: Comparison of gene-level alteration frequency by BTC Subtypes Table S5: Comparison of pathway-level alteration frequency by BTC Subtypes Table S6: Actionable alterations in patients without targeted therapy due to unavailability Table S7: Comparison of clinical characteristics between treatment groups Table S8: Comparison of gene-level alterations between treatment groups Table S9: Summary of OS univariate analysis (Full cohort) Table S10: Overall Survival analysis of Molecularly Defined Subgroups